* ENDOTIS PHARMA *
2003 - IDF
Romainville
(near Paris)
www.endotis.com Discovery, Drugs
Key words: Small-glyco drugs (SGD), Thrombosis, Cancer
Mission: to discover and develop Small-glyco drugs (SGD) for application in thrombosis and oncology
Clients: Prescribers
contact@endotis.com
Age: 7 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Start-up |
Managing Dir.-CEO: Woller (Charles) [born 1949, M.D., Ph.D. Clinical pharmacology, MBA, ex-Neuro3D (founder), Cadus, Roche France (Managing Director), Warner Lambert, Akzo]
Sc.Dir.-CSO: Petitou (Maurice) [Ph.D., ex-Sanofi, Lauréat Prix Charles Mentzer 2009]
Fin.Dir.-CFO: Degove (Stéphane) [Sup de Co (Paris), ex-Sanofi, Orica, OC&C]
BusDev:
Financers (Hist.): Endeavour Vision, NIF SMBC Ventures, Sofinnova Partners | Turnover (M€) : n.a.
Total funding (M€) : 34.0
Last funding (M€) : 25.0
Focus : Multiple
Position : Preclin
Company confirm : neutral |
History | DATE | MILESTONE | TYPE | TIME | | 2009 .05 | Clinical trial (phase I) for EP42675, a first in class synthetic parenteral anticoagulant (completed, positive) | CLIN | [6 years] |
| 2008 .01 | 2nd round-financing : 25.0 M€, by the Wellcome Trust | RFINB | [4 years] |
| 2007 .11 | Licensing-out of anti-thrombotics to Akzo Nobel | LICOUT | [4 years] |
| 2007 .06 | Nomination : Charles Woller, new CEO, replacing David Béchard | ORGN | [4 years] |
| 2005 .07 | 1st round-financing : 9.0 M€, by Sofinnova C.V. and others | RFINA | [2 years] |
| 2003 .02 | Company founded by David Béchard (CEO) [Ph.D. oncology, ex-OC&C], Philippe Lassalle [M.D., ex-Roche, Inserm], Franck Vivet [ex-Aventis, Baxter, Fournier] | ORGF | [0 year] | Actualisation / Updating: 07-Sept-2009 |
|
